DK1373529T3 - Tau-opati model - Google Patents
Tau-opati modelInfo
- Publication number
- DK1373529T3 DK1373529T3 DK02702181T DK02702181T DK1373529T3 DK 1373529 T3 DK1373529 T3 DK 1373529T3 DK 02702181 T DK02702181 T DK 02702181T DK 02702181 T DK02702181 T DK 02702181T DK 1373529 T3 DK1373529 T3 DK 1373529T3
- Authority
- DK
- Denmark
- Prior art keywords
- tau
- alzheimer
- disease
- opati
- model
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Signal Processing For Digital Recording And Reproducing (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0104685.3A GB0104685D0 (en) | 2001-02-26 | 2001-02-26 | Tau-opathy model |
| PCT/BE2002/000022 WO2002068663A1 (en) | 2001-02-26 | 2002-02-25 | Tau-opathy model |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1373529T3 true DK1373529T3 (da) | 2008-08-18 |
Family
ID=9909505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02702181T DK1373529T3 (da) | 2001-02-26 | 2002-02-25 | Tau-opati model |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050009019A1 (da) |
| EP (1) | EP1373529B1 (da) |
| AT (1) | ATE393229T1 (da) |
| DE (1) | DE60226220T2 (da) |
| DK (1) | DK1373529T3 (da) |
| ES (1) | ES2306755T3 (da) |
| GB (1) | GB0104685D0 (da) |
| WO (1) | WO2002068663A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7799535B1 (en) | 1997-12-09 | 2010-09-21 | Arch Development Corporation | Methods for identifying factors that control the folding of amyloid proteins of diverse origin |
| ATE532874T1 (de) * | 2001-02-15 | 2011-11-15 | Univ Chicago | Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen |
| AU2004231746A1 (en) * | 2003-04-16 | 2004-11-04 | Whitehead Institute For Biomedical Research | Yeast ectopically expressing abnormally processed proteins and uses therefor |
| EP2709728B1 (en) * | 2011-05-20 | 2019-01-23 | Oligomerix, Inc. | Tau protease methods of use |
| GB201319656D0 (en) | 2013-11-07 | 2013-12-25 | Univ Leuven Kath | A yeast model for synergistic toxicity |
| SG11201608084TA (en) * | 2014-04-17 | 2016-10-28 | Boehringer Ingelheim Rcv Gmbh | Recombinant host cell engineered to overexpress helper proteins |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993003369A1 (en) * | 1991-08-01 | 1993-02-18 | Voorheis Paul H | Diagnostic method for alzheimer's disease |
| KR940021073A (ko) * | 1993-03-02 | 1994-10-17 | 미야베 요시가즈 | 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i |
| CA2157774A1 (en) * | 1993-04-07 | 1994-10-13 | Christopher John Marshall | Methods for screening of substances for therapeutic activity and yeast for use therein |
| GB9316727D0 (en) * | 1993-08-12 | 1993-09-29 | Inst Of Psychiatry | Models of alzheimers's disease |
| US5691137A (en) * | 1994-08-30 | 1997-11-25 | Brandeis University | Methods of screening candidate agents for biological activity using yeast cells |
| US5952217A (en) * | 1997-09-23 | 1999-09-14 | Bristol-Myers Squibb Company | Recombinant yeast cell and assay using same |
| US7799535B1 (en) * | 1997-12-09 | 2010-09-21 | Arch Development Corporation | Methods for identifying factors that control the folding of amyloid proteins of diverse origin |
| NZ515956A (en) * | 1999-07-02 | 2004-04-30 | Janssen Pharmaceutica Nv | Transgenic animals as models for neurodegenerative disease |
| GB0100119D0 (en) * | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
-
2001
- 2001-02-26 GB GBGB0104685.3A patent/GB0104685D0/en not_active Ceased
-
2002
- 2002-02-25 DE DE60226220T patent/DE60226220T2/de not_active Expired - Lifetime
- 2002-02-25 AT AT02702181T patent/ATE393229T1/de not_active IP Right Cessation
- 2002-02-25 DK DK02702181T patent/DK1373529T3/da active
- 2002-02-25 US US10/468,542 patent/US20050009019A1/en not_active Abandoned
- 2002-02-25 EP EP02702181A patent/EP1373529B1/en not_active Revoked
- 2002-02-25 ES ES02702181T patent/ES2306755T3/es not_active Expired - Lifetime
- 2002-02-25 WO PCT/BE2002/000022 patent/WO2002068663A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE60226220D1 (de) | 2008-06-05 |
| WO2002068663A1 (en) | 2002-09-06 |
| ES2306755T3 (es) | 2008-11-16 |
| US20050009019A1 (en) | 2005-01-13 |
| EP1373529A1 (en) | 2004-01-02 |
| ATE393229T1 (de) | 2008-05-15 |
| DE60226220T2 (de) | 2009-08-20 |
| EP1373529B1 (en) | 2008-04-23 |
| GB0104685D0 (en) | 2001-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1641483T3 (da) | Fusionsproteiner | |
| BR0215383A (pt) | proteases que produzem resposta imunogênica alterada e métodos de fabricação e uso das mesmas | |
| ECSP088262A (es) | Proteínas de fusión de albúmina | |
| HUP0202882A2 (en) | Novel b7-4 molecules and uses therefor | |
| DE60330923D1 (de) | Menschliche Koagulationsfaktor VII Polypeptide | |
| EP1289551A4 (en) | HUMAN POLYPEPTIDES THAT LEAD TO THE DISAPPEARANCE OF CELLS, IN PARTICULAR LYMPHOID TUMOR CELLS | |
| EP1751282A4 (en) | PRODUCTION OF HOST CELLS CONTAINING MULTIPLE INTEGRATED VECTORS THROUGH SERIAL TRANSDUCTION | |
| WO2009001260A3 (en) | Cosmetic use of apolipoprotein d type proteins | |
| ATE487737T1 (de) | 32 humane sekretierte proteine | |
| DK1373529T3 (da) | Tau-opati model | |
| WO2000068247A3 (en) | Serine proteases | |
| WO2001062891A3 (en) | 207 human secreted proteins | |
| ATE464320T1 (de) | Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk) | |
| CY1111004T1 (el) | Χρησιμες συνθεσεις για τη ρυθμιση της δρασης του γονιδιου της παρκινης | |
| ATE539086T1 (de) | Interleukin-11-fusionsproteine | |
| ATE503834T1 (de) | Bibliotheken rekombinanter chimärischer proteine | |
| WO2003082206A3 (en) | Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses | |
| DE60142356D1 (de) | 18480 humane proteinkinasemoleküle und ihre verwendungen | |
| WO2002074921A3 (en) | Methods for isolating proteins expressed by dendritic cells | |
| WO2005035564A3 (en) | Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders | |
| DE60237236D1 (de) | Ein mitglied der menschlichen proteinkinasefamilie, und verwendungen dafür | |
| ATE343632T1 (de) | Mutiertes nurr1 gen | |
| WO2002099066A3 (en) | 20 human secreted proteins | |
| DE60231816D1 (de) | Menschliche alpha2-delta4-calciumkanal-untereinheit codierende cdna | |
| AU2002350406A1 (en) | Identification of ses-3 (spr-5) in c. elegans and the uses of the same |